Key Points
- Tilray insider Denise Faltischek bought 2,500 shares at an average price of $4.78, spending $11,950 and increasing her holdings by 1.80% to 141,285 shares.
- Tilray’s stock opened at $4.64, with a market capitalization of about $541 million and a 52-week range of $3.67 to $23.20. The company recently reported a quarterly loss of $0.43 per share, substantially missing the $0.01-loss consensus, despite revenue exceeding estimates.
- Analyst views remain mixed, but the stock carries a “Moderate Buy” consensus rating and an average price target of $11.00; TD Securities recently upgraded the shares to “strong buy,” while other firms issued downgrades.
Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) insider Denise Faltischek acquired 2,500 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $4.78 per share, for a total transaction of $11,950.00. Following the purchase, the insider owned 141,285 shares of the company's stock, valued at $675,342.30. This represents a 1.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Tilray Brands Stock Performance
TLRY opened at $4.64 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 2.21 and a debt-to-equity ratio of 0.22. The stock's fifty day moving average is $4.64 and its two-hundred day moving average is $6.17. The company has a market capitalization of $540.79 million, a P/E ratio of -4.30 and a beta of 1.90. Tilray Brands, Inc. has a 52 week low of $3.67 and a 52 week high of $23.20.
Tilray Brands (NASDAQ:TLRY - Get Free Report) last issued its earnings results on Tuesday, July 28th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%.The firm had revenue of $281.71 million during the quarter, compared to analysts' expectations of $246.30 million. Analysts forecast that Tilray Brands, Inc. will post -0.34 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on TLRY. Weiss Ratings lowered shares of Tilray Brands from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, May 13th. Wall Street Zen downgraded shares of Tilray Brands from a "hold" rating to a "sell" rating in a research report on Saturday. TD Cowen reduced their price target on shares of Tilray Brands from $7.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, July 14th. Finally, TD Securities raised shares of Tilray Brands to a "strong-buy" rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $11.00.
Get Our Latest Report on TLRY
More Tilray Brands News
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: CFO Carl A. Merton purchased 10,000 shares for approximately $46,200, increasing his holdings by 7.71%. Insider buying can signal management confidence that the stock is undervalued. SEC insider ownership filing
- Positive Sentiment: Insider Denise M. Faltischek bought 2,500 shares worth approximately $11,950, increasing her ownership by 1.80%. The additional insider purchase reinforces the positive signal from management. SEC insider ownership filing
- Positive Sentiment: TD Securities upgraded Tilray, potentially improving sentiment toward the shares and signaling a more favorable view of the company’s outlook. Tilray Brands upgraded at TD Securities
- Positive Sentiment: Tilray’s distribution segment delivered double-digit growth in fiscal 2026, making it the company’s strongest reported growth driver. Tilray distribution growth article
- Neutral Sentiment: Tilray appeared on a Nasdaq Composite watchlist, increasing visibility but offering no direct change to the company’s fundamentals or earnings outlook. Why Tilray is a Nasdaq Composite watchlist stock
- Negative Sentiment: Although Tilray reported record fiscal 2026 results, analysts remain concerned that acquisitions make it difficult to measure true organic growth. That uncertainty weakens the case for buying the stock despite headline growth. Tilray record fiscal 2026 results analysis
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC bought a new position in shares of Tilray Brands in the 4th quarter worth $38,000. Cerity Partners LLC boosted its position in Tilray Brands by 98.5% during the second quarter. Cerity Partners LLC now owns 92,560 shares of the company's stock valued at $38,000 after purchasing an additional 45,929 shares in the last quarter. Marex Group plc bought a new stake in Tilray Brands during the second quarter valued at about $40,000. Hilton Capital Management LLC purchased a new position in Tilray Brands in the second quarter valued at about $41,000. Finally, Essential Partners LLC grew its stake in Tilray Brands by 110,137.5% in the first quarter. Essential Partners LLC now owns 8,819 shares of the company's stock valued at $57,000 after purchasing an additional 8,811 shares during the last quarter. 9.35% of the stock is currently owned by hedge funds and other institutional investors.
About Tilray Brands
(
Get Free Report)
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
